- Home
- AMLX
as of 01-16-2026 3:40pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.3B | IPO Year: | 2022 |
| Target Price: | $17.43 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.60 - $16.96 | Next Earning Date: | 03-03-2026 |
| Revenue: | N/A | Revenue Growth: | -77.06% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered AMLX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
Co-Chief Executive Officer
Avg Cost/Share
$11.09
Shares
7,715
Total Value
$85,596.38
Owned After
3,317,632
SEC Form 4
Co-Chief Executive Officer
Avg Cost/Share
$11.09
Shares
7,715
Total Value
$85,589.44
Owned After
3,317,586
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$11.11
Shares
3,326
Total Value
$36,953.86
Owned After
177,104
SEC Form 4
Director
Avg Cost/Share
$12.45
Shares
8,100
Total Value
$100,845.00
Owned After
63,100
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$14.35
Shares
6,580
Total Value
$94,418.39
Owned After
175,756
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Jan 6, 2026 | Sell | $11.09 | 7,715 | $85,596.38 | 3,317,632 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Jan 6, 2026 | Sell | $11.09 | 7,715 | $85,589.44 | 3,317,586 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Jan 6, 2026 | Sell | $11.11 | 3,326 | $36,953.86 | 177,104 | |
| Firestone Karen | AMLX | Director | Dec 23, 2025 | Buy | $12.45 | 8,100 | $100,845.00 | 63,100 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Dec 1, 2025 | Sell | $14.35 | 6,580 | $94,418.39 | 175,756 |
Compare AMLX vs Leading Stocks
See how AMLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.